# Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

> **NCT01505608** · PHASE1,PHASE2 · TERMINATED · sponsor: **Giselle Sholler** · enrollment: 14 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** TPI 287
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01505608
- **Lead sponsor:** Giselle Sholler
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505608, "Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01505608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*